Please ensure Javascript is enabled for purposes of website accessibility

Why BioCryst Pharmaceuticals Rose 8% on Thursday

By Cory Renauer – Aug 5, 2021 at 4:08PM

Key Points

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's first commercial drug launch keeps exceeding expectations.

What happened

Shares of BioCryst Pharmaceuticals (BCRX -1.77%) rose after the company's second-quarter earnings call. A stronger than expected performance from the company's shiny new sales force drove the biotech stock 8.7% higher as of 3:58 p.m EDT on Thursday.

So what 

Last December, the FDA approved BioCryst Pharmaceuticals' first drug, an oral treatment for hereditary angioedema (HAE) called Orladeyo. Takeda (TAK 1.46%) already markets a blockbuster injectable treatment for HAE patients and it was expected to pressure BioCryst's first drug launch.

Two people looking at data on a computer screen.

Image source: Getty Images.

Second-quarter Orladeyo sales came in at $28.5 million, which was around 161% more than the company recorded during the first quarter. The number of doctors prescribing Orladeyo grew by approximately 50% in the second quarter and a majority of new prescriptions went to HAE patients who switched from their previous treatment.

Now what

The next new program rolling through BioCryst's development pipeline, BCX9930, is set to begin enrolling paroxysmal nocturnal hemoglobinuria (PNH) patients in a pivotal study. If results fall in line with its previous success in a smaller trial, the company could have a second potential blockbuster drug to launch before the end of 2022. 

Positive signals from BCX930 and Orladeyo have pushed shares of BioCryst around 136% higher this year but there's probably more fuel in the tank. At recent prices, this company still sports a relatively modest $3.2 billion market cap. 

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.